ACUR.US Acura Pharmaceuticals Inc
- Market cap
- USD 19.8K
- P/E
- -
- P/B
- 24.11x
- ROE
- -493.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2021.
Is ACUR.US undervalued?
Graham numberThe Graham number of Acura Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Acura Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Acura Pharmaceuticals Inc yet.
Acura Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Acura Pharmaceuticals Inc
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and …
Full company profileAcura Pharmaceuticals Inc financial statements
Acura Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 123K | 751K | 8.59M | 4.46M | 2.97M | 410K | 2.66M | 3.57M | 1.56M |
| Gross Profit | - | -241K | -4.26M | 7.60M | 3.99M | 2.84M | 410K | 2.66M | 3.57M | - |
| Operating Income | -9.74M | -14.1M | -12.2M | -4.00M | -6.56M | -5.23M | -3.92M | -725K | -758K | -1.21M |
| EBITDA | - | - | - | - | - | -4.93M | -3.17M | -3.04M | -633K | -589K |
| Net Income | -9.67M | -13.9M | -13.2M | -4.99M | -7.39M | -5.68M | -3.84M | -3.77M | -1.21M | -879K |
| EPS | - | -0.29 | - | -0.42 | -0.62 | -0.27 | -0.18 | -0.18 | -0.06 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 29.1M | 28.6M | 16.0M | 17.0M | 8.21M | 4.60M | 2.15M | 2.56M | 1.74M | 860K |
| Total Liabilities | 1.42M | 10.7M | 11.0M | 9.06M | 7.03M | 4.63M | 5.77M | 7.30M | 7.63M | 682K |
| Shareholders' Equity | 27.6M | 17.9M | 5.05M | 7.90M | 1.18M | -27.0K | -3.62M | -4.74M | -5.89M | 178K |
| Cash & Short-term Investments | 27.4M | 26.1M | 774K | 13.3M | 5.18M | 2.22M | 91.0K | 862K | 413K | 65.0K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -7.04M | -13.7M | -11.0M | -3.69M | -5.56M | -4.51M | -3.91M | -618K | -719K | -742K |
| Capital Expenditure | 147K | 23.0K | 135K | 214K | 75.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | - | - | -4.51M | -3.91M | -618K | -719K | -742K |
| Ratios | ||||||||||
| ROE | -35.0% | -77.6% | -261.5% | -63.2% | -624.5% | - | - | - | - | -493.8% |
| ROA | -33.3% | -48.6% | -82.4% | -29.4% | -90.0% | -123.4% | -178.5% | -147.3% | -69.6% | -102.2% |
| Net Profit Margin | - | -11,301.6% | -1,758.9% | -58.1% | -165.5% | -191.6% | -937.1% | -142.0% | -33.8% | -56.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Acura Pharmaceuticals Inc dividends
Acura Pharmaceuticals Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:5 on Aug 28, 2015.
Who owns Acura Pharmaceuticals Inc
- Insiders 1.69%
- Institutions 0.00%
- Public & others 98.31%
- Shares outstanding 66.0M
- Free float 64.2M
Acura Pharmaceuticals Inc company profile
- Company name
- Acura Pharmaceuticals Inc
- Ticker
- ACUR.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 9
- Fiscal year end
- December
- Address
- 616 N. North Court, Palatine, IL, United States, 60067
- Phone
- 847 705 7709
- Website
- acurapharm.com
About Acura Pharmaceuticals Inc
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
Acura Pharmaceuticals Inc management
2- Mr. Robert B. JonesCEO, President & Director · born 1959
- Mr. Robert A. Seiser CPA, Ph.D.CFO, Senior VP, Treasurer & Corporate Controller · born 1964